ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.
A New York-based company named Siga Technologies has won FDA approval for its oral formulation of tecovirimat, used to treat smallpox, in case there occurs an outbreak.
Sanction of a single 300mg dose of GlaxoSmithKline’s tafenoquine in patients 16 years and above for the "radical cure" of malaria was advocated by an FDA advisory committee on finding significant evidence for its efficacy and safety.
EchoNous announced that it has been granted FDA 510(k) clearance for its EchoNous Vein ultrasound device which could improve peripheral IV catheter placements. This system could provide real-time clear mages of superficial and deeper veins.
The U.S. Food and Drug Administration approved the first autonomous artificial intelligence diagnostic system, IDx-DR and the University of Iowa Healthcare has become the first healthcare organization to implement it.
Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
Kibbutz Shefayim from an Israel-based startup company named Zebra Medical Vision announced that it has successfully received FDA clearance for an algorithm, which could aid physicians to quantify a patient’s coronary artery calcification.
Onitor Track is an advanced biometric, data-driven program which aids in weight loss. Onitor Track combines a personalized weight loss and nutrition program with a dual-positioned wearable via an app.
NHS Digital and NHS England together have devised a free NHS app to book GP appointments in a swifter and user-friendly way. This novel NHS app will be launched in December 2018, allowing patients to access their health records in a safe and secure manner.
The premarket approval of Pulmonx’s Zephyr Endobronchial Valve to treat severe emphysema has green-lighted by the FDA. Zephyr is a pencil eraser-sized device delivered directly to the lung in a minimally invasive procedure. After the successful delivery, the device stops air from entering diseased parts of the lung during breathing. This mechanism prevents the air from getting trapped by damaged alveoli and stops the breathing difficulties.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.